[ad_1]
Capped vials are displayed during fill and pack testing for large-scale production and supply of the COVID-19 candidate vaccine from the University of Oxfords, AZD1222
- A volunteer at the Oxford and AstraZeneca vaccine trial in Brazil has died.
- The 28-year-old man died of complications from Covid-19, O Globo newspaper of Brazil Y CNN Brazil reported. He is the first person to die during any company’s COVID-19 vaccine trial.
- According to O Globo, he was in the control group and had been given a placebo instead of the test vaccine.
- A representative of the Oxford Vaccine Group, which is developing the vaccine with AstraZeneca, told Business Insider that it would continue testing because “there have been no concerns about safety.”
- Visit the Business Insider home page for more stories.
A participant in the AstraZeneca coronavirus vaccine trial in Brazil died, marking the world’s first death from a COVID-19 vaccine trial.
The deceased was a 28-year-old man from Rio de Janeiro who died of complications from COVID-19, Brazil’s O Globo newspaper and CNN Brazil reported Wednesday.
Both outlets reported that he had volunteered to participate in AstraZeneca’s clinical trials for his vaccine, which is being developed with the Oxford Vaccine Group.
According to O Globo, the man had been in the trial’s control group and received a placebo instead of the trial vaccine. Anvisa, Brazil’s health agency, said it was informed of the death on Monday, CNN Brazil reported. The agency has refused to reveal the identity of the participant.
Oxford Vaccine Group has told Business Insider that the trial will continue.
“After careful evaluation of this case in Brazil, there have been no concerns about the safety of the clinical trial and the independent review, in addition to the Brazilian regulator, has recommended that the trial continue,” said Joanna Bagniewska, a spokeswoman for the group.
“All major medical incidents, whether the participants are in the control group or the COVID-19 vaccine group, are reviewed independently,” he added.
The Federal University of São Paulo, where AstraZeneca trials are taking place in Brazil, also told Reuters: “Everything is progressing as expected, with no record of serious vaccine-related complications involving any of the volunteers. participants”.
The trial would have been suspended if the person who had died had received a dose of the trial vaccine, Reuters reported.
About 10,000 people have signed up to participate in the AstraZeneca trials in Brazil, and so far 8,000 have received the trial vaccine or a placebo, O Globo reported.
The death in Brazil follows news in early September that AstraZeneca had stopped a trial in the UK for six days after a participant fell ill.
On October 12, Johnson & Johnson also stopped its vaccine trial after a participant experienced an unexplained illness.
Pausing vaccine trials is a common precaution taken by scientists and drug manufacturers.
AstraZeneca’s candidate vaccine is one of the few that is in the late stages of clinical trials.
Receive a daily update on your cell phone with all our latest news – click here.
Receive the best of our site by email daily: Click here.
Also from Business Insider South Africa:
[ad_2]
